ESMO 2017 Highlights in Haematological Malignancies: Emphasis on Biosimilars and t-AML

Speaker: Michele Ghielmini

Michele Ghielmini talks about the level of importance given to biosimilars in this ESMO 2017 Congress and their activity in haematological malignancies.

Michele Ghielmini talks about the level of importance given to biosimilars in this ESMO 2017 Congress and their activity in haematological malignancies.

He comments on the results of a confirmatory phase III trial for rituximab biosimilar. The response rate, Pharmacokinetics results, side-effects reports and progression-free survival were the same with rituximab and its biosimilar which led to the conclusion that they are equivalent. These findings contributed to the dossier submitted to the health authorities and resulted in the authorisation for the biosimilar to be substituted for rituximab.

The study on the risk of developing AML after treatment with radioactive iodine in thyroid cancer patients shows that we shouldn’t give more treatment than what is needed. Remco Molenaar reports that the risk of developing AML after RAI therapy is real and underlines that the benefit of this treatment has only been demonstrated in high risk patients. Moreover, the type of secondary leukaemia is similar to the ones induced by etoposide or anthracyclines, with a peak of incidence after only two years, and a prognosis worse than the de-novo AMLs.

 

Abstracts

  • 994O - Equivalent Efficacy of a Biosimilar Rituximab and Reference Rituximab in Previously Untreated Advanced Follicular Lymphoma: Extended Results of ASSIST-FL, a Confirmatory Phase III Study
  • 996O - Risk of developing acute myeloid leukemia (AML) in well-differentiated thyroid cancer (WDTC) patients treated with radioactive iodine (RAI): a population-based study

More resources from ESMO 2017 Congress